All In Biotech

Drug Trial Radar · NCT06425900

A Study to Assess Sebaceous Gland Changes and Constituents of Sebum (Skin Oil) Induced by Clascoterone 1% Cream in Acne Patients

Histologic and Liquid Chromatography Mass Spectrometry (LCMS) Evaluation of the Sebaceous Gland Changes Induced by Clascoterone Cream 1%

Last checked: Nov 20, 2026Latest source record: Jan 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

10

Actual

Start

Jul 1, 2024

Primary completion

Mar 2026

Study completion Mar 2026

Sponsor

Sponsor type
Industry
First posted
May 23, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 35 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

to compare facial sebaceous gland morphology after 3 months of clascoterone cream 1% treatment and to compare facial sebum constituents at baseline to facial sebum constituents after 3 months of clascoterone cream 1% treatment

Conditions

  • Acne Vulgaris

Interventions

  • Winlevi (Clascoterone) cream 1%Drug

    Dosed twice daily (BID)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The primary efficacy endpoint is the histologic demonstration of reduced facial sebaceous gland size when comparing baseline to 3 months of clascoterone cream 1 % treatment.Time frame: Week 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Dermatology Consulting Services, PLLC

    High Point, North Carolina

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.